γ-Secretase-dependent amyloid-β is increased in Niemann-Pick type C: A cross-sectional study

Neurology

Volumn 76, Issue 4, 2011, Pages 366-372

  Mattsson, N ^a   Zetterberg, H ^a   Bianconi, S ^b   Yanjanin, N M ^b   Fu, R ^b   Mansson J E ^a   Porter, F D ^b   Blennow, K ^a  

^a UNIVERSITY OF GOTHENBURG   (Sweden)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN[1-40]; AMYLOID BETA PROTEIN[1-42]; APOLIPOPROTEIN E; GAMMA SECRETASE; MIGLUSTAT; TAU PROTEIN;

ADOLESCENT; ADULT; ARTICLE; CEREBROSPINAL FLUID ANALYSIS; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DISEASE DURATION; DISEASE SEVERITY; FEMALE; GENOTYPE; HUMAN; LIPID STORAGE; MALE; NERVE CELL MEMBRANE; NERVE FIBER DEGENERATION; NIEMANN PICK DISEASE; ONSET AGE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN METABOLISM; PROTEIN SECRETION;

EID: 79251560973     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/WNL.0b013e318208f4ab     Document Type: Article

References (40)

1. Querfurth HW, LaFerla FM. Alzheimer's disease. N Engl J Med 2010;362:329-344.
2. Grimm MO, Grimm HS, Hartmann T. Amyloid beta as a regulator of lipid homeostasis. Trends Mol Med 2007;13: 337-344.
3. Hirsch-Reinshagen V, Burgess BL, Wellington CL. Why lipids are important for Alzheimer disease? Mol Cell Bio-chem 2009;326:121-129.
4. Zha Q, Ruan Y, Hartmann T, Beyreuther K, Zhang D. GM1 ganglioside regulates the proteolysis of amyloid precursor protein. Mol Psychiatry 2004;9:946-952.
5. Fassbender K, Simons M, Bergmann C, et al. Simvastatin strongly reduces levels of Alzheimer's disease beta-amyloid peptides Abeta 42 and Abeta 40 in vitro and in vivo. Proc Natl Acad Sci USA 2001;98:5856-5861.
6. Simons M, Keller P, De Strooper B, Beyreuther K, Dotti CG, Simons K. Cholesterol depletion inhibits the generation of beta-amyloid in hippocampal neurons. Proc Natl Acad Sci USA 1998;95:6460-6464.
7. Wahrle S, Das P, Nyborg AC, et al. Cholesterol-dependent gamma-secretase activity in buoyant cholesterol-rich membrane microdomains. Neurobiol Dis 2002;9:11-23.
8. Vanier MT, Millat G. Niemann-Pick disease type C. Clin Genet 2003;64:269-281.
9. Imrie J, Dasgupta S, Besley GT, et al. The natural history of Niemann-Pick disease type C in the UK. J Inherit Metab Dis 2007;30:51-59.
10. Sevin M, Lesca G, Baumann N, et al. The adult form of Niemann-Pick disease type C. Brain 2007;130:120-133.
11. Zervas M, Dobrenis K, Walkley SU. Neurons in Niemann-Pick disease type C accumulate gangliosides as well as unesterified cholesterol and undergo dendritic and axonal alterations. J Neuropathol Exp Neurol 2001;60: 49-64.
12. Zervas M, Somers KL, Thrall MA, Walkley SU. Critical role for glycosphingolipids in Niemann-Pick disease type C. Curr Biol 2001;11:1283-1287.
13. von Elm E, Altman DG, Egger M, Pocock SJ, Gotzsche PC, Vandenbroucke JP. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. Lancet 2007;370:1453-1457.
14. Mattsson N, Savman K, Osterlundh G, Blennow K, Zetterberg H. Converging molecular pathways in human neural development and degeneration. Neurosci Res 2010; 66:330-332.
15. Yanjanin NM, Velez JI, Gropman A, et al. Linear clinical progression, independent of age of onset, in Niemann-Pick disease, type C. Am J Med Genet B Neuropsychiatr Genet 2010;153B:132-140.
16. Patterson MC, Vecchio D, Prady H, Abel L, Wraith JE. Miglustat for treatment of Niemann-Pick C disease: a randomised controlled study. Lancet Neurol 2007;6:765-772.
17. Olsson A, Vanderstichele H, Andreasen N, et al. Simultaneous measurement of beta-amyloid(1-42), total tau, and phosphorylated tau (Thr181) in cerebrospinal fluid by the xMAP technology. Clin Chem 2005;51:336-345.
18. Portelius E, Price E, Brinkmalm G, et al. A novel pathway for amyloid precursor protein processing. Neurobiol Aging Epub 2009.
19. Hartmann T, Bieger SC, Bruhl B, et al. Distinct sites of intracellular production for Alzheimer's disease A be-ta40/42 amyloid peptides. Nat Med 1997;3:1016-1020.
20. Osenkowski P, Ye W, Wang R, Wolfe MS, Selkoe DJ. Direct and potent regulation of gamma-secretase by its lipid microenvironment. J Biol Chem 2008;283:22529-22540.
21. Lloyd-Evans E, Platt FM. Lipids on trial: the search for the offending metabolite in Niemann-Pick type C disease. Traffic 2010;11:419-428.
22. Gondre-Lewis MC, McGlynn R, Walkley SU. Cholesterol accumulation in NPC1-deficient neurons is ganglioside dependent. Curr Biol 2003;13:1324-1329.
23. Ory DS. The Niemann-Pick disease genes; regulators of cellular cholesterol homeostasis. Trends Cardiovasc Med 2004;14:66-72.
24. Walkley SU, Suzuki K. Consequences of NPC1 and NPC2 loss of function in mammalian neurons. Biochim Biophys Acta 2004;1685:48-62.
25. Bergmans BA, De Strooper B. Gamma-secretases: from cell biology to therapeutic strategies. Lancet Neurol 2010; 9:215-226.
26. Frykman S, Hur JY, Franberg J, et al. Synaptic and endo-somal localization of active gamma-secretase in rat brain. PLoS One 2010;5:e8948.
27. Karten B, Peake KB, Vance JE. Mechanisms and consequences of impaired lipid trafficking in Niemann-Pick type C1-deficient mammalian cells. Biochim Biophys Acta 2009;1791:659-670.
28. Vassar R, Kovacs DM, Yan R, Wong PC. The beta-secretase enzyme BACE in health and Alzheimer's disease: regulation, cell biology, function, and therapeutic potential. J Neurosci 2009;29:12787-12794.
29. Benjannet S, Elagoz A, Wickham L, et al. Post-translational processing of beta-secretase (beta-amyloid-converting enzyme) and its ectodomain shedding: the pro-and transmembrane/cytosolic domains affect its cellular activity and amyloid-beta production. J Biol Chem 2001; 276:10879-10887.
30. Walter J, Fluhrer R, Hartung B, et al. Phosphorylation regulates intracellular trafficking of beta-secretase. J Biol Chem 2001;276:14634-14641.
31. Cordy JM, Hussain I, Dingwall C, Hooper NM, Turner AJ. Exclusively targeting beta-secretase to lipid rafts by GPI-anchor addition up-regulates beta-site processing of the amyloid precursor protein. Proc Natl Acad Sci USA 2003;100:11735-11740.
32. Vetrivel KS, Meckler X, Chen Y, et al. Alzheimer disease Abeta production in the absence of S-palmitoylation-dependent targeting of BACE1 to lipid rafts. J Biol Chem 2009;284:3793-3803.
33. Sankaranarayanan S, Holahan MA, Colussi D, et al. First demonstration of cerebrospinal fluid and plasma A beta lowering with oral administration of a beta-site amyloid precursor protein-cleaving enzyme 1 inhibitor in nonhu-man primates. J Pharmacol Exp Ther 2009;328:131-140.
34. Kojro E, Gimpl G, Lammich S, Marz W, Fahrenholz F. Low cholesterol stimulates the nonamyloidogenic pathway by its effect on the alpha-secretase ADAM 10. Proc Natl Acad Sci USA 2001;98:5815-5820.
35. Kivipelto M, Helkala EL, Laakso MP, et al. Midlife vascular risk factors and Alzheimer's disease in later life: longitudinal, population based study. BMJ 2001;322:1447-1451.
36. Kim J, Basak JM, Holtzman DM. The role of apolipopro-tein E in Alzheimer's disease. Neuron 2009;63:287-303.
37. Refolo LM, Pappolla MA, LaFrancois J, et al. A cholesterol-lowering drug reduces beta-amyloid pathology in a transgenic mouse model of Alzheimer's disease. Neu-robiol Dis 2001;8:890-899.
38. Wolozin B, Kellman W, Ruosseau P, Celesia GG, Siegel G. Decreased prevalence of Alzheimer disease associated with 3-hydroxy-3-methyglutaryl coenzyme A reductase inhibitors. Arch Neurol 2000;57:1439-1443.
39. Simons M, Schwarzler F, Lutjohann D, et al. Treatment with simvastatin in normocholesterolemic patients with Alzheimer's disease: a 26-week randomized, placebo-controlled, double-blind trial. Ann Neurol 2002;52:346-350.
40. Sparks DL, Sabbagh MN, Connor DJ, et al. Atorvastatin for the treatment of mild to moderate Alzheimer disease: preliminary results. Arch Neurol 2005;62:753-757.